These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18441512)

  • 41. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
    Liam CK; Pang YK; Leow CH
    Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful treatment of lung cancer with gefitinib and EGFR mutation status determination using EBUS-TBNA samples in an extremely old patient.
    Nishimura H; Nakajima T; Itakura M; Shingyoji M; Iizasa T; Kimura H
    Intern Med; 2009; 48(21):1905-7. PubMed ID: 19881244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
    Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
    J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia.
    Suzumura T; Yonesaka K; Tsukuda H; Fukuoka M
    BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24626382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
    Yang H; Wang R; Peng S; Chen L; Li Q; Wang W
    Oncotarget; 2016 Mar; 7(13):16273-81. PubMed ID: 26919104
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.
    Takenaka T; Yamagata M; Fukuda A; Sonoda T
    BMJ Case Rep; 2011 Sep; 2011():. PubMed ID: 22679236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
    Izumi H; Touge H; Igishi T; Makino H; Nishii-Ito S; Takata M; Nakazaki H; Ueda Y; Matsumoto S; Kodani M; Kurai J; Takeda K; Sakamoto T; Yanai M; Tanaka N; Nirodi CS; Shimizu E
    Int J Oncol; 2015 Mar; 46(3):989-98. PubMed ID: 25573239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disease flare after gefitinib discontinuation.
    Akamatsu H; Ono A; Shukuya T; Tsuya A; Nakamura Y; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Yamamoto N; Takahashi T
    Respir Investig; 2015 Mar; 53(2):68-72. PubMed ID: 25745851
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.
    Isobe K; Kakimoto A; Mikami T; Kaburaki K; Kobayashi H; Yoshizawa T; Nakano Y; Makino T; Otsuka H; Sano G; Sugino K; Sakamoto S; Takai Y; Tochigi N; Iyoda A; Homma S
    Oncol Rep; 2018 Jul; 40(1):331-338. PubMed ID: 29767258
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
    Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cerebrospinal fluid tumor markers predict treatment response in a patient with carcinomatous meningitis.
    Lin J; Wu S; Tian C; Shi Q
    J Int Med Res; 2021 Jan; 49(1):300060520987946. PubMed ID: 33512249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
    Ibrahim U; Saqib A; Atallah JP
    Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
    Han B; Jin B; Chu T; Niu Y; Dong Y; Xu J; Gu A; Zhong H; Wang H; Zhang X; Shi C; Zhang Y; Zhang W; Lou Y; Zhu L; Pei J
    Int J Cancer; 2017 Sep; 141(6):1249-1256. PubMed ID: 28560853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.
    Jackman DM; Cioffredi LA; Jacobs L; Sharmeen F; Morse LK; Lucca J; Plotkin SR; Marcoux PJ; Rabin MS; Lynch TJ; Johnson BE; Kesari S
    Oncotarget; 2015 Feb; 6(6):4527-36. PubMed ID: 25784657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
    Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Retrospective study of a series of 26 carcinomatous meningitis secondary to lung cancer].
    Hammerer V; Pauli G; Quoix E
    Bull Cancer; 2005 Nov; 92(11):989-94. PubMed ID: 16316833
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib].
    Imai K; Ashitani J; Yanagi S; Kodama T; Kyoraku Y; Sano A; Matsumoto N; Nakazato M
    Nihon Kokyuki Gakkai Zasshi; 2007 Jan; 45(1):71-5. PubMed ID: 17313031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
    Dhruva N; Socinski MA
    J Clin Oncol; 2009 Aug; 27(22):e31-2. PubMed ID: 19487379
    [No Abstract]   [Full Text] [Related]  

  • 60. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
    Fujiwara Y; Kiura K; Toyooka S; Takigawa N; Tokumo M; Hotta K; Aoe M; Tabata M; Matsuo K; Date H; Tanimoto M
    Lung Cancer; 2006 Apr; 52(1):99-103. PubMed ID: 16503086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.